Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 11/20 | 0.69 |
| ▸ | RAB9A | P51151 | 11/20 | 0.69 |
| ▸ | GAA | P10253 | 6/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | HTT | P42858 | 2/20 | 0.69 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.65 |
| ▸ | GFER | P55789 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13996646 | 0.87 | NPC1 (0.54) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL18171839 | 0.81 | ALDH1A1 (0.64) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL14432042 | 0.80 | ALDH1A1 (0.59) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL9919056 | 0.78 | ALDH1A1 (0.50) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL4592448 | 0.76 | NPC1 (0.85) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL17792673 | 0.76 | SHMT2 (1.00) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL31035886 | 0.75 | MAPT (0.68) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL22930416 | 0.74 | MAPT (1.00) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL212384 | 0.74 | NPC1 (0.71) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL764284 | 0.74 | NPC1 (0.66) | NPC1RAB9AGAAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| US-8871746-B2 | Antiviral drugs for treatment of arenavirus infection | Kineta Four, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-8629170-B2 | Anti-viral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20110172281-A1 | Anti-Viral Drugs for Treatment of Arenavirus Infection | SIGA TECHNOLOGIES INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7977365-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7872037-B2 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | SIGA TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | US | disclosed |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | SIGA TECHNOLOGIES, INC. | 2007-11-01 | — | — | US | disclosed |
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | GLAXO GROUP LIMITED (GB) | 2007-08-16 | — | — | US | disclosed |
| EP-0878196-B1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6133258-A | PYRIDOTHIAZINE DERIVATIVE; FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, MULTIPLE SCLEROSIS, PAIN, GLAUCOMA | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0878196-A1 | KAINIC ACID NEURONOTOXICITY INHIBITORS AND PYRIDOTHIAZINE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1998-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191426-A1 | Derivatives of 3-aminocarbonylquinoline, pharmaceutical compositions containing them and processes and intermediates for their preparation | PDE4B, PDE4A, PDE3B | NPC1 3028/4885RAB9A 1429/4885GAA 355/4885 |
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | NPC1 324/4885RAB9A 2310/4885GAA 445/4885 |
| US-20110172281-A1 | Anti-Viral Drugs for Treatment of Arenavirus Infection | GK, GALK1, KLK7 | NPC1 152/4885RAB9A 3813/4885GAA 57/4885 |
| US-20070254934-A1 | Antiviral drugs for treatment of arenavirus infection | GK, GALK1, GZMB | NPC1 193/4885RAB9A 3895/4885GAA 70/4885 |
| US-20080300265-A1 | ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVRUS INFECTION | GK, MAVS, ZC3HAV1 | NPC1 165/4885RAB9A 3470/4885GAA 29/4885 |
| US-20120071447-A1 | Antiviral Drugs for Treatment of Arenavirus Infection | ZC3HAV1, GZMB, GTF3C3 | NPC1 337/4885RAB9A 3973/4885GAA 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.